RESEARCH AGREEMENTResearch Agreement • September 18th, 2023 • Lexeo Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
This Agreement is made by and between Lexeo Therapeutics, Inc. (“Company”) with offices at 430 East 29th Street, 14th Floor, New York, NY 10016, and The Regents of the University of California on behalf of its San Diego campus, having its office at 9500 Gilman Drive, La Jolla, CA 92093-0934, (“University”), (each may be individually referred to as a “Party” and collectively, as the “Parties”), effective as of the date of last signature below (“Effective Date”).
CONSULTING AGREEMENTConsulting Agreement • September 18th, 2023 • Lexeo Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Consulting Agreement (“Agreement”) is made by and between Dr. Eric Adler (“Consultant”) and LEXEO Therapeutics, Inc. (the “Company”) (each a “Party” and collectively the “Parties”). The Company and Consultant hereby agree as follows:
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • September 18th, 2023 • Lexeo Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of August 10, 2021, by and among Lexeo Therapeutics, Inc., a Delaware corporation (the “Company”) and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”.
STOCK PURCHASE AGREEMENT BY AND AMONG LEXEO THERAPEUTICS, INC., STELIOS THERAPEUTICS, INC., THE STOCKHOLDERS, AND STOCKHOLDERS’ REPRESENTATIVE Dated as of July 16, 2021Stock Purchase Agreement • September 18th, 2023 • Lexeo Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
THIS STOCK PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of July 16, 2021, by and among LEXEO Therapeutics, Inc., a Delaware corporation (the “Purchaser”), Stelios Therapeutics, Inc., a Delaware corporation (the “Company”), The Cystinosis Research Foundation, Eric Adler, M.D., Farah Sheikh, Ph.D., Jeffrey M. Ostrove, Ph.D., and Stephanie Cherqui, Ph.D. (each, a “Stockholder” and, together, the “Stockholders”), and Jeffrey M. Ostrove, Ph.D., in his capacity as representative for Stockholders (“Stockholders’ Representative”).
LICENSE AGREEMENTLicense Agreement • September 18th, 2023 • Lexeo Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This LICENSE AGREEMENT (the “Agreement”) is entered into on the Closing Date (as defined below) (the “Effective Date”) between ADVERUM BIOTECHNOLOGIES, INC., a Delaware corporation with a place of business at 800 Saginaw Dr., Redwood City CA 94063 (“Licensor”), and LEXEO THERAPEUTICS LLC, a Delaware limited liability company with a place of business at 430 East 29th St, 14th Floor New York, NY 10016 (“Licensee”). Licensor and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
